Last reviewed · How we verify
ACETAZOLAMIDE oral capsule
Acetazolamide inhibits carbonic anhydrase, reducing bicarbonate reabsorption in the kidney and promoting diuresis and alkalinization of urine.
Acetazolamide inhibits carbonic anhydrase, reducing bicarbonate reabsorption in the kidney and promoting diuresis and alkalinization of urine. Used for Glaucoma and ocular hypertension, Acute mountain sickness, Epilepsy.
At a glance
| Generic name | ACETAZOLAMIDE oral capsule |
|---|---|
| Also known as | Esomeprazole (Nexium®, AstraZeneca Korea, Co. Ltd., Seoul, Korea) 40 mg, bid, for 7 days, Amoxicillin (Kymoxin®, Yuhan Co. Ltd., Seoul, Korea) 1 g, bid, for 7 days, Clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg, bid, for 7 days, Acetazolamide (Diamox®, SK Chemicals Co. Ltd., Suwon, Korea) 250mg, bid, for 7 days, Glauseta |
| Sponsor | University of Zurich |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology, Neurology, Urology |
| Phase | FDA-approved |
Mechanism of action
Acetazolamide is a carbonic anhydrase inhibitor that decreases the conversion of carbon dioxide and water to bicarbonate and hydrogen ions in the proximal convoluted tubule of the nephron. This inhibition reduces bicarbonate reabsorption, leading to increased urinary bicarbonate and sodium excretion, mild diuresis, and systemic metabolic acidosis. The drug also reduces aqueous humor production in the eye and decreases intracranial pressure.
Approved indications
- Glaucoma and ocular hypertension
- Acute mountain sickness
- Epilepsy
- Idiopathic intracranial hypertension
- Periodic paralysis
Common side effects
- Paresthesia (tingling in extremities)
- Altered taste (especially carbonated beverages)
- Hypokalemia (low potassium)
- Metabolic acidosis
- Nephrolithiasis (kidney stones)
- Stevens-Johnson syndrome (rare)
Key clinical trials
- Managing Opioid Related Sleep Apnea With Acetazolamide (PHASE2)
- Preoperative Acetazolamide (PHASE4)
- HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men (PHASE4)
- Acetazolamide on REM OSA (PHASE1, PHASE2)
- Sleep Apnea in Elderly (PHASE4)
- HighCycle Study: Acetazolamide, High Altitude and Plasma Volume (PHASE4)
- Sleep Disordered Breathing With Opioid Use (PHASE1, PHASE2)
- HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACETAZOLAMIDE oral capsule CI brief — competitive landscape report
- ACETAZOLAMIDE oral capsule updates RSS · CI watch RSS
- University of Zurich portfolio CI